US Stock Market News | Northeast Securities maintains "Buy" rating, Hutchmed China surges over 8%
On Friday, HUTCHMED's stock price rose, with the stock up over 8% to $19.245 as of the time of publication. The Hong Kong stock market closed with a more than 7% increase today. A research report from Northeast Securities pointed out that the company has made rapid progress in research and development recently, with multiple products advancing simultaneously, demonstrating excellent clinical data and competitive landscape. The company is continuously promoting the globalization of its products, which is expected to continue catalyzing the fundamental value of the company. In addition, the company has a rich pipeline reserve, a broad market space for its products, and continues to achieve overseas sales volume. Northeast Securities maintains a "buy" rating for HUTCHMED
According to the Zhitong Finance and Economics APP, on Friday, HUTCHMED (HCM.US) saw its stock price rise, with the stock up over 8% to $19.245 as of the time of writing. The Hong Kong stock market also closed up more than 7% today. A research report from Northeast Securities pointed out that the company has made rapid progress in research and development recently, with multiple products making simultaneous efforts, demonstrating excellent clinical data and competitive landscape. The company is continuously advancing its global product strategy, which is expected to continue to catalyze the fundamental value of the company. In addition, the company has a rich pipeline reserve, a broad market space for its products, and continues to achieve overseas sales growth. Northeast Securities maintains a "buy" rating on HUTCHMED